Andrew David Levin - 18 Dec 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role
Director
Signature
/s/ Adi Osovsky, Attorney-in-Fact
Issuer symbol
VOR
Transactions as of
18 Dec 2025
Net transactions value
$0
Form type
4
Filing time
19 Dec 2025, 18:14:26 UTC
Previous filing
05 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Levin Andrew David Director C/O VOR BIOPHARMA INC., 500 BOYLSTON STREET, SUITE 1350, BOSTON /s/ Adi Osovsky, Attorney-in-Fact 19 Dec 2025 0001867539

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VOR Stock Option (Right to Buy) Award $0 +3,000 $0.000000 3,000 18 Dec 2025 Common Stock 3,000 $12.80 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.